景峰医药(000908) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥100,110,799.34, a decrease of 0.46% compared to ¥100,575,702.29 in the same period last year[3] - The net profit attributable to shareholders was -¥11,899,583.20, representing a significant decline of 960.04% from -¥1,122,560.52 year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥10,770,642.19, down 682.74% from ¥1,848,275.03 in the previous year[3] - Net profit for the current period was a loss of ¥11,179,695.86, compared to a profit of ¥371,857.08 in the previous period[16] - The company reported a comprehensive loss of ¥11,163,598.24, compared to a comprehensive income of ¥405,781.67 in the previous period[17] Cash Flow - The net cash flow from operating activities increased by 32.49% to ¥11,453,424.33, compared to ¥8,644,488.81 in the same period last year[3] - Operating cash inflow totaled ¥99,223,217.11, down 32.8% from ¥147,729,200.68 in the previous period[19] - Cash outflow from operating activities decreased to ¥87,769,792.78, down 37.0% from ¥139,084,711.87 in the previous period[20] - Cash flow from investment activities generated a net inflow of ¥1,894,591.35, compared to a net outflow of ¥415,900.00 in the previous period[20] - Cash outflow for investment activities decreased significantly to ¥47,400.00 from ¥587,700.00 in the previous period[20] - Cash flow from financing activities resulted in a net outflow of ¥23,274,399.69, worsening from a net outflow of ¥5,302,864.12 in the previous period[20] - The impact of exchange rate changes on cash and cash equivalents was a negative ¥15,959.86, compared to a negative ¥957,811.59 in the previous period[20] - The ending balance of cash and cash equivalents was ¥48,843,904.51, down from ¥14,923,877.12 in the previous period[20] - The company reported a significant increase in cash received from operating activities related to other business activities, totaling ¥22,234,418.93, up from ¥9,580,238.57[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥923,256,475.22, a decrease of 1.78% from ¥939,983,853.40 at the end of the previous year[3] - Total liabilities decreased slightly to ¥949,549,360.56 from ¥955,113,140.50, a reduction of 0.59%[13] - The company's equity attributable to shareholders decreased by 14.54% to ¥69,904,815.75 from ¥81,796,189.16 at the end of the previous year[3] - The company's equity attributable to shareholders decreased to ¥69,904,815.75 from ¥81,796,189.16, a decline of 14.56%[13] Operating Costs and Expenses - Total operating costs increased to ¥108,545,441.39, up 4.83% from ¥103,667,185.25 in the previous period[15] - Research and development expenses increased to ¥2,259,822.81, up 17.06% from ¥1,929,948.31 in the previous period[16] - Employee compensation payments decreased to ¥20,745,329.84, down 12.7% from ¥23,773,401.07 in the previous period[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 34,311[8] - Basic and diluted earnings per share were both -0.0135, compared to -0.0013 in the previous period[17] Other Income - The company reported a significant increase in other operating income by 162.92%, primarily due to arbitration compensation received[6] Return on Assets - The weighted average return on net assets was -15.69%, down 17.27% from 1.58% in the previous year[3]